$STRO
SUTRO BIOPHARMA, INC. Stock $stro

$stro Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-K Financial Statement

#000156459021013945 Filed on March 18, 2021

Income Statement

Concept	2021 Q1	2020 Q4	2020 Q3
Revenue	$14.66M	$8.278M	$17.82M
YoY Change	104.98%	-26.78%	45.17%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$11.11M	$10.38M	$9.080M
YoY Change	27.55%	19.31%	11.82%
% of Gross Profit
Research & Development	$22.56M	$22.74M	$19.36M
YoY Change	28.05%	30.76%	14.58%
% of Gross Profit
Depreciation & Amortization	$1.291M	$1.170M	$970.0K
YoY Change	17.47%	-4.1%	-21.14%
% of Gross Profit
Operating Expenses	$33.67M	$33.12M	$19.36M
YoY Change	91.09%	26.95%	-22.59%
Operating Profit	-$19.01M
YoY Change
Interest Expense	-$11.35M	-$34.70M	$27.76M
YoY Change	2602.38%	346900.0%	-15522.22%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$30.36M	-$59.54M	$17.14M
YoY Change	54.9%	302.57%	-232.77%
Income Tax
% Of Pretax Income
Net Earnings	-$30.36M	-$59.54M	$17.14M
YoY Change	54.93%	302.62%	-232.74%
Net Earnings / Revenue	-207.09%	-719.3%	96.16%
Basic Earnings Per Share		-$1.48	$0.46
Diluted Earnings Per Share	-$661.3K	-$1.48	$0.45
COMMON SHARES
Basic Shares Outstanding	45.89M		36.89M
Diluted Shares Outstanding			37.88M

Balance Sheet

Concept	2021 Q1	2020 Q4	2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$251.2M	$368.1M	$281.2M
YoY Change	117.68%	212.21%	124.6%
Cash & Equivalents	$55.82M	$206.2M	$64.37M
Short-Term Investments	$195.4M	$162.0M	$216.9M
Other Short-Term Assets	$7.500M	$4.500M	$3.600M
YoY Change	150.0%	2.27%	24.14%
Inventory
Prepaid Expenses
Receivables	$7.200M	$5.559M	$7.500M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$266.0M	$378.2M	$292.3M
YoY Change	108.63%	194.15%	115.61%
LONG-TERM ASSETS
Property, Plant & Equipment	$14.80M	$12.94M	$11.90M
YoY Change	55.79%	34.28%	39.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$74.60M	$0.00	$0.00
YoY Change	425.35%	-100.0%	-100.0%
Other Assets	$3.100M	$2.122M	$3.000M
YoY Change	14.81%	-16.62%	27.61%
Total Long-Term Assets	$92.50M	$15.93M	$14.90M
YoY Change	250.38%	-42.71%	-58.74%
TOTAL ASSETS
Total Short-Term Assets	$266.0M	$378.2M	$292.3M
Total Long-Term Assets	$92.50M	$15.93M	$14.90M
Total Assets	$358.5M	$394.1M	$307.2M
YoY Change	132.94%	152.04%	78.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.900M	$5.544M	$4.900M
YoY Change	1.72%	-0.72%	7.72%
Accrued Expenses	$4.500M	$8.823M	$5.900M
YoY Change	55.17%	46.63%	27.48%
Deferred Revenue		$14.60M
YoY Change		-24.98%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Short-Term Liabilities	$22.70M	$29.60M	$29.90M
YoY Change	-29.06%	-10.22%	-16.62%
LONG-TERM LIABILITIES
Long-Term Debt	$24.70M	$24.55M	$24.40M
YoY Change	2.07%	176.53%	343.64%
Other Long-Term Liabilities	$3.900M	$481.0K	$8.800M
YoY Change	-75.0%	258.96%	6721.71%
Total Long-Term Liabilities	$28.60M	$25.03M	$33.20M
YoY Change	-28.14%	177.76%	489.8%
TOTAL LIABILITIES
Total Short-Term Liabilities	$22.70M	$29.60M	$29.90M
Total Long-Term Liabilities	$28.60M	$25.03M	$33.20M
Total Liabilities	$51.20M	$62.06M	$63.10M
YoY Change	-28.69%	5.94%	2.15%
SHAREHOLDERS EQUITY
Retained Earnings	-$258.2M	-$227.9M	-$168.3M
YoY Change	19.93%	16.41%	-6.99%
Common Stock		$559.8M
YoY Change		90.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$307.3M	$332.0M	$244.1M
YoY Change
Total Liabilities & Shareholders Equity	$358.5M	$394.1M	$307.2M
YoY Change	132.98%	152.04%	78.94%

Cashflow Statement

Concept	2021 Q1	2020 Q4	2020 Q3
OPERATING ACTIVITIES
Net Income	-$30.36M	-$59.54M	$17.14M
YoY Change	54.93%	302.62%	-232.74%
Depreciation, Depletion And Amortization	$1.291M	$1.170M	$970.0K
YoY Change	17.47%	-4.1%	-21.14%
Cash From Operating Activities	-$30.43M	-$18.88M	-$17.69M
YoY Change	62.43%	43.57%	9.74%
INVESTING ACTIVITIES
Capital Expenditures	-$2.380M	-$1.630M	-$2.970M
YoY Change	-411.93%	-20.49%	350.0%
Acquisitions
YoY Change
Other Investing Activities	-$119.4M	$17.43M	$3.270M
YoY Change	-381.49%	74.47%	-68.8%
Cash From Investing Activities	-$121.7M	$15.80M	$300.0K
YoY Change	-392.36%	98.99%	-96.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.826M	144.9M	17.27M
YoY Change	-88.37%	-8238.2%	-1641.96%
NET CHANGE
Cash From Operating Activities	-30.43M	-18.88M	-17.69M
Cash From Investing Activities	-121.7M	15.80M	300.0K
Cash From Financing Activities	1.826M	144.9M	17.27M
Net Change In Cash	-150.3M	141.8M	-120.0K
YoY Change	-489.42%	-2128.33%	-98.38%
FREE CASH FLOW
Cash From Operating Activities	-$30.43M	-$18.88M	-$17.69M
Capital Expenditures	-$2.380M	-$1.630M	-$2.970M
Free Cash Flow	-$28.05M	-$17.25M	-$14.72M
YoY Change	43.87%	55.41%	-4.79%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020	stro	Warrants Issued To Lenders WarrantsIssuedToLenders	619000
CY2018	stro	Conversion Of Redeemable Convertible Preferred Stock And Warrants Into Common Stock Upon Ipo Net Of Issuance Costs ConversionOfRedeemableConvertiblePreferredStockAndWarrantsIntoCommonStockUponIPONetOfIssuanceCosts	187244000
CY2020	us-gaap	Substantial Doubt About Going Concern Within One Year SubstantialDoubtAboutGoingConcernWithinOneYear	false
CY2020	stro	Period For Cumulative Ownership Change PeriodForCumulativeOwnershipChange	P3Y
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2019	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	us-gaap:AccountingStandardsUpdate201409Member
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.732
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.727
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.546
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.874
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.749
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.624
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.002
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.014
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.027
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.016
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.026
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.031
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-38662
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	131539000
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2020	dei	City Area Code CityAreaCode	650
CY2018	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-47000
CY2020	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	41498000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-35317000
CY2020	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-0926186
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	310 Utah Avenue
CY2020	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 150
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2020	dei	Local Phone Number LocalPhoneNumber	392-8412
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6017000
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	14603000
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	19465000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4406000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	378182000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	128568000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12935000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9633000
CY2019Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	15609000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2122000
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2545000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	872000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	15000
CY2020Q4	us-gaap	Assets Assets	394111000
CY2019Q4	us-gaap	Assets Assets	156370000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5544000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5584000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8823000
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	261100000
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	45892331
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4960000
CY2019Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	112904000
CY2020Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	41644000
CY2019Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	1050000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5559000
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6298000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4486000
CY2019Q4	us-gaap	Debt Current DebtCurrent	1000000
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	901000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	32967000
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	16195000
CY2019Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	409000
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	8876000
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	134000
CY2019Q4	us-gaap	Liabilities Liabilities	58581000
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4777000
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4539000
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-490000
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1457000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	11917000
CY2020	stro	Remeasurement Of Liability Awards RemeasurementOfLiabilityAwards	-19000
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23098969
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23098969
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	23000
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	293346000
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	165000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-195745000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	97789000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	156370000
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38419000
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	54262000
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21380000
CY2020	stro	Interest And Other Expense Net InterestAndOtherExpenseNet	4077000
CY2019	stro	Interest And Other Expense Net InterestAndOtherExpenseNet	4350000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-55744000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-35317000
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1285000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1861000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1441000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	734000
CY2018	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	187244000
CY2018	stro	Stock Issued During Period Value Preferred Stock Warrants Exercised Value StockIssuedDuringPeriodValuePreferredStockWarrantsExercisedValue	268000
CY2018	stro	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	134000
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	74436000
CY2018	stro	Stock Issued During Period Value With Private Placement StockIssuedDuringPeriodValueWithPrivatePlacement	10000000
CY2018	stro	Payment Of Note Receivable By Stockholder PaymentOfNoteReceivableByStockholder	208000
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1260000
CY2019	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	297000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10312000
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	212000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-55744000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	97789000
CY2020	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	314000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11917000
CY2020	stro	Warrants Issued During Period Value In Connection With Debt Refinancing WarrantsIssuedDuringPeriodValueInConnectionWithDebtRefinancing	619000
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	227252000
CY2020	stro	Stock Issued During Period Value Through At The Market Sale StockIssuedDuringPeriodValueThroughAtTheMarketSale	23803000
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-36000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-32128000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	332048000
CY2020	us-gaap	Profit Loss ProfitLoss	-32128000
CY2019	us-gaap	Profit Loss ProfitLoss	-55744000
CY2018	us-gaap	Profit Loss ProfitLoss	-35317000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4297000
CY2018	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	527000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	10312000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	2872000
CY2020	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	41498000
CY2019	stro	Remeasurement Of Liability Awards RemeasurementOfLiabilityAwards	115000
CY2018	stro	Remeasurement Of Liability Awards RemeasurementOfLiabilityAwards	1827000
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-587000
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-468000
CY2018	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-337000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-739000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3809000
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	865000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	80000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-947000
CY2018	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2578000
CY2019	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	186000
CY2018	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	551000
CY2020	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-931000
CY2019	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	67000
CY2018	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-48000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-14957000
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-20186000
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	42305000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-67802000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-65023000
CY2020	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	25000000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	12683000
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	130741000
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	196226000
CY2018	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	81463000
CY2020	stro	Proceeds From Maturities Of Marketable Securities ProceedsFromMaturitiesOfMarketableSecurities	116385000
CY2019	stro	Proceeds From Maturities Of Marketable Securities ProceedsFromMaturitiesOfMarketableSecurities	128576000
CY2018	stro	Proceeds From Maturities Of Marketable Securities ProceedsFromMaturitiesOfMarketableSecurities	2750000
CY2020	stro	Proceeds From Sales Of Marketable Securities ProceedsFromSalesOfMarketableSecurities	22000000
CY2019	stro	Proceeds From Sales Of Marketable Securities ProceedsFromSalesOfMarketableSecurities	20000000
CY2020	stro	Payments To Acquire Equipment And Leasehold Improvements PaymentsToAcquireEquipmentAndLeaseholdImprovements	7129000
CY2019	stro	Payments To Acquire Equipment And Leasehold Improvements PaymentsToAcquireEquipmentAndLeaseholdImprovements	3481000
CY2018	stro	Payments To Acquire Equipment And Leasehold Improvements PaymentsToAcquireEquipmentAndLeaseholdImprovements	1557000
CY2020	stro	Proceeds From Exercise Of Options For Vaxcyte Shares ProceedsFromExerciseOfOptionsForVaxcyteShares	89000
CY2018	stro	Proceeds From Exercise Of Options For Vaxcyte Shares ProceedsFromExerciseOfOptionsForVaxcyteShares	80000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	604000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-51131000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-80190000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	251415000
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	-327000
CY2020	us-gaap	Repayments Of Debt RepaymentsOfDebt	10000000
CY2019	us-gaap	Repayments Of Debt RepaymentsOfDebt	5000000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1861000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	180000
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	134000
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	314000
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	297000
CY2020	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1285000
CY2019	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1260000
CY2018	stro	Proceeds Interest From Payment Of Note Receivable By Stockholder ProceedsInterestFromPaymentOfNoteReceivableByStockholder	208000
CY2018	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	84739000
CY2018	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	74436000
CY2018	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	10000000
CY2018	stro	Proceeds From Preferred Stock Warrants Exercises ProceedsFromPreferredStockWarrantsExercises	268000
CY2018	stro	Proceeds From A Research Development And Commercialization Agreement ProceedsFromAResearchDevelopmentAndCommercializationAgreement	1000000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-4184000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	170785000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	202049000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-120338000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	103278000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4975000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	125313000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	22035000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	207024000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4975000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	125313000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	1675000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	1049000
CY2018	us-gaap	Interest Paid Net InterestPaidNet	1275000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	546000
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	270000
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	205000
CY2020	stro	Offering Costs Included In Accounts Payable OfferingCostsIncludedInAccountsPayable	361000
CY2020	stro	Embedded Interest Associated With Program Fees EmbeddedInterestAssociatedWithProgramFees	1852000
CY2019	stro	Embedded Interest Associated With Program Fees EmbeddedInterestAssociatedWithProgramFees	3144000
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	125298000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	266724
CY2018	stro	Reclassification Of Redeemable Convertible Preferred Stock Warrant Liability To Equity ReclassificationOfRedeemableConvertiblePreferredStockWarrantLiabilityToEquity	734000
CY2020	us-gaap	Nature Of Operations NatureOfOperations	<p style="margin-top:12pt;margin-bottom:0pt;text-indent:2.86%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.Organization and Principal Activities</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Description of Business </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.64%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sutro Biopharma, Inc. (the “Company”) is a clinical stage drug discovery, development and manufacturing company focused on leveraging its integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF<sup style="font-size:85%;line-height:120%;vertical-align:top">®</sup>, to create a broad variety of optimally designed, next-generation protein therapeutics, initially for cancer. The Company was incorporated on April 21, 2003, and is headquartered in South San Francisco, California. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.64%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in one business segment, the development of biopharmaceutical products. <span style="font-size:12pt;"> </span> <span style="font-size:12pt;"> </span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.64%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Liquidity </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:2.86%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">At-The-Market Sales</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.57%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, the Company sold an aggregate of 2,614,286 shares of its common stock through its At-the-Market (“ATM Facility”) pursuant to its Common Stock Sales Agreement<sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup>dated October 4, 2019 with Cowen and Company, LLC, as sales agent. The gross proceeds from these sales were approximately $24.6 million, before deducting fees of approximately $0.8 million, resulting in net proceeds of approximately $23.8 million to the Company. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:2.86%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">2020 Public Offerings</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.57%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 14, 2020, the Company closed a public offering of 12,650,000 shares of its common stock at a public offering price of $7.75 per share, which included the exercise in full of the underwriters’ option to purchase 1,650,000 shares of common stock. <span style="Background-color:#FFFFFF;color:#000000;">The gross proceeds from this offering were approximately $98.0 million, before deducting approximately $6.6 million of underwriting discounts and commissions and other offering expenses, resulting in net proceeds of approximately $91.4 million to the Company. </span> </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.57%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 11, 2020, the Company closed a public offering of 6,900,000 shares of its common stock at a public offering price of $21.00 per share, which included the exercise in full of the underwriters’ option to purchase 900,000 shares of common stock. <span style="Background-color:#FFFFFF;color:#000000;">The gross proceeds from this offering were approximately $144.9 million, before deducting approximately $9.1 million of underwriting discounts and commissions and other offering expenses, resulting in net proceeds of approximately $135.8 million to the Company. </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Term Loan</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:2.86%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 28, 2020, the Company entered into a loan and security agreement (the “Loan and Security Agreement”) with Oxford Finance LLC (“Oxford”), as the collateral agent and a lender, and Silicon Valley Bank, as a lender (together with Oxford, the “Lenders”), pursuant to which the Lenders agreed to lend the Company up to an aggregate of $25.0 million in a series of term loans (the “Term A Loan”). Upon entering into the Loan and Security Agreement, the Company borrowed $25.0 million from the Lenders, with approximately $9.6 million of such amount applied to the repayment of the outstanding principal, interest and final payment fees owed pursuant to a prior loan and security agreement dated August 4, 2017 with the Lenders. The net proceeds from the Term Loans under the Loan and Security Agreement may be used to satisfy the Company’s future working capital needs and to fund its general business requirements. Please see an expanded discussion on the Loan and Security Agreement in Note 7<span style="font-family:Times New Roman;"> </span><span style="font-style:italic;">Loan and Security Agreement</span>.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.64%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred significant losses and has negative cash flows from operations. As of December 31, 2020, there was an accumulated deficit of $227.9 million. Management expects to continue to incur additional substantial losses in the foreseeable future as a result of the Company’s research and development and other operational activities. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.64%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company had unrestricted cash, cash equivalents and marketable securities of $326.5 million, which is available to fund future operations. The Company will need to raise additional capital to support the completion of its research and development activities and to support its operations.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.64%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes that its unrestricted cash, cash equivalents and marketable securities as of December 31, 2020 will enable the Company to maintain its operation for a period of at least 12 months following the filing date of its financial statements. </p>
CY2020	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2003-04-21
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-227900000
CY2020Q4	stro	Unrestricted Cash Cash Equivalents And Marketable Securities At Carrying Value UnrestrictedCashCashEquivalentsAndMarketableSecuritiesAtCarryingValue	326500000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	900000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	15000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4960000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	15000
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	15000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4975000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	125313000
CY2020Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss	14700000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3000
CY2019Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss	4500000
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2020	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2019	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	324845000
CY2020Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	0
CY2018	stro	Deemed Dividend DeemedDividend	0
CY2017	stro	Deemed Dividend DeemedDividend	0
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	324973000
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	131499000
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	168000
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3000
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	131664000
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3000
CY2020	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0
CY2019Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	15600000
CY2019	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0
CY2020Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	14600000
CY2020Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12M
CY2020Q4	stro	Convertible Preferred Stock Warrant Liability Fair Value ConvertiblePreferredStockWarrantLiabilityFairValue	200000
CY2019Q4	stro	Convertible Preferred Stock Warrant Liability Fair Value ConvertiblePreferredStockWarrantLiabilityFairValue	100000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	49762000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	43481000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	36827000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	33848000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12935000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9633000
CY2020Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	200000
CY2019Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	400000
CY2020	us-gaap	Interest Expense Debt InterestExpenseDebt	2300000
CY2019	us-gaap	Interest Expense Debt InterestExpenseDebt	1100000
CY2018	us-gaap	Interest Expense Debt InterestExpenseDebt	1600000
CY2020	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0808
CY2019	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0872
CY2018	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0839
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	500000
CY2019	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	200000
CY2018	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	200000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	266724
CY2020Q4	stro	Lessee Operating Leases And Sublease Liability Payments Due Next Twelve Months LesseeOperatingLeasesAndSubleaseLiabilityPaymentsDueNextTwelveMonths	5742000
CY2020Q4	stro	Lessee Operating Leases And Sublease Liability Payments Due Year Two LesseeOperatingLeasesAndSubleaseLiabilityPaymentsDueYearTwo	5183000
CY2020Q4	stro	Lessee Operating Leases And Sublease Liability Payments Due Year Three LesseeOperatingLeasesAndSubleaseLiabilityPaymentsDueYearThree	6310000
CY2020Q4	stro	Lessee Operating Leases And Sublease Liability Payments Due Year Four LesseeOperatingLeasesAndSubleaseLiabilityPaymentsDueYearFour	7476000
CY2020Q4	stro	Lessee Operating Leases And Sublease Liability Payments Due Year Five And Thereafter LesseeOperatingLeasesAndSubleaseLiabilityPaymentsDueYearFiveAndThereafter	24034000
CY2020Q4	stro	Lessee Operating Leases And Sublease Liability Payments Due LesseeOperatingLeasesAndSubleaseLiabilityPaymentsDue	48745000
CY2020	stro	Potential Financial Benefit Base Rent Abatement PotentialFinancialBenefitBaseRentAbatement	5200
CY2020	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4700
CY2019	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	3600
CY2018	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	3600
CY2020	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one vote per share
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8331103
CY2019Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	7357234
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1200000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	200000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	200000
CY2020Q4	stro	Liability Attributable To Call Option Plan LiabilityAttributableToCallOptionPlan	109000
CY2019Q4	stro	Liability Attributable To Call Option Plan LiabilityAttributableToCallOptionPlan	76000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.59
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.71
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.48
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11917000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10312000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2872000
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	257834
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	191153
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	8890
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	75571
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.005
CY2019	stro	Effective Income Tax Rate Reconciliation Asc606 Adoption Percent EffectiveIncomeTaxRateReconciliationASC606AdoptionPercent	-0.039
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.061
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.020
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.047
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.003
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.093
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.049
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.075
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.019
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.013
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.001
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.347
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.227
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.327
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	47549000
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	31010000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	25175000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	20098000
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	3629000
CY2019Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	7680000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	6460000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	3718000
CY2020Q4	stro	Deferred Tax Assets Fixed Assets DeferredTaxAssetsFixedAssets	917000
CY2019Q4	stro	Deferred Tax Assets Fixed Assets DeferredTaxAssetsFixedAssets	795000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	83730000
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	63301000
CY2020Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	9298000
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	9298000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	74432000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	63301000
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	11100000
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	12600000
CY2020	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	Events which cause limitations in the amount of net operating losses that the Company may utilize in any one year include, but are not limited to, a cumulative ownership change of more than 50%, as defined, over a three-year testing period.
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	4900000
CY2019Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	3800000
CY2018Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	2800000
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3783000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2795000
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2305000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1090000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1005000
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	741000
CY2020	stro	Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions	29000
CY2019	stro	Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions	-17000
CY2018	stro	Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions	-251000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4902000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3783000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2795000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-32128000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-55744000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-35317000
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	32573469
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22958577
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5758875
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.99
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.43
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-6.13
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-14250000
CY2019Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.65
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.56
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.60
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.62
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-13793000
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6314039
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4321697
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3524187
CY2020Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8278000
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	17823000
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9469000
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7152000
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-59544000
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	17139000
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	29872000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-19595000
CY2020Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.48
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.46
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.00
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.84
CY2020Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.48
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.45
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.94
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.84
CY2019Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11305000
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12277000
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10525000
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8629000
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-14789000
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-12912000

Files In Submission

Name	View Source	Status
0001564590-21-013945-index-headers.html	Edgar Link	pending
0001564590-21-013945-index.html	Edgar Link	pending
0001564590-21-013945.txt	Edgar Link	pending
0001564590-21-013945-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
genb0v2mvruz000001.jpg	Edgar Link	pending
genb0v2mvruz000002.jpg	Edgar Link	pending
genb0v2mvruz000003.jpg	Edgar Link	pending
genb0v2mvruz000004.jpg	Edgar Link	pending
genb0v2mvruz000005.jpg	Edgar Link	pending
genb0v2mvruz000006.jpg	Edgar Link	pending
gpkaqc2g5gaf000001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
stro-10k_20201231.htm	Edgar Link	pending
stro-10k_20201231_htm.xml	Edgar Link	completed
stro-20201231.xsd	Edgar Link	pending
stro-20201231_cal.xml	Edgar Link	unprocessable
stro-20201231_def.xml	Edgar Link	unprocessable
stro-20201231_lab.xml	Edgar Link	unprocessable
stro-20201231_pre.xml	Edgar Link	unprocessable
stro-ex1011_205.htm	Edgar Link	pending
stro-ex1024_531.htm	Edgar Link	pending
stro-ex231_14.htm	Edgar Link	pending
stro-ex311_13.htm	Edgar Link	pending
stro-ex312_12.htm	Edgar Link	pending
stro-ex321_11.htm	Edgar Link	pending
stro-ex322_9.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$STRO
SUTRO BIOPHARMA, INC. Stock $stro

2021 Q1 Form 10-K Financial Statement

#000156459021013945 Filed on March 18, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STRO SUTRO BIOPHARMA, INC. Stock $stro

2021 Q1 Form 10-K Financial Statement

#000156459021013945 Filed on March 18, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STRO
SUTRO BIOPHARMA, INC. Stock $stro